Nystatin Oral Suspension Articles
Novartis MS drug: less relapse than Avonex
22 December 2008
Xeloda plus chemo reduces recurrence 34%
22 December 2008
Hi-Tech reports record sales for 2nd-qtr 2008
22 December 2008
Barr's adenovirus vacc BLA accepted by FDA
22 December 2008
Strong Ph II data for Chroma's tosedostat in AML/MDS
22 December 2008
J&J's paliperidone LA shows 13-week control
22 December 2008
ASH hears strong data on Novartis
22 December 2008
Novo partners with Merrion over Insulin analogs
15 December 2008
AcelRx' oral sufentanilin shows strong Ph II results
15 December 2008
Pooled RECORD data "confirm Xarelto better than Lovenox"
15 December 2008
Positive Ph III data for GSK ITP drug
15 December 2008
Sosei reports strong early results for SD118
15 December 2008
Alkermes addiction drug enters Ph I testing
15 December 2008
Merck & Co's 2009 outlook below predictions due to forex effects and restructuring costs
15 December 2008
Beximco cleared to start exporting drugs Gulf
8 December 2008
Dosing begins in Ph Ib trial of Genaera's trodusquemine
8 December 2008
Anadys' HCV drug gets FDA fast-track status
8 December 2008
UPDATE: PDCO has good news for Lux Bio and others
8 December 2008
Arpida initiates major cost-cutting program
8 December 2008
DOR gets $1.5M from Sigma under orBec deal
8 December 2008
Astex to present strong data on two candidates at ASH
8 December 2008
PDCO has good news for Lux Bio and others
8 December 2008
Alpharma relents, accepting King Pharma
1 December 2008
NSCLC data could signal comeback for AZ's Iressa
1 December 2008
FDA approves GSK and Ligand's Promacta
1 December 2008
FDA approves J&J's tapentadol
1 December 2008
Cephalon swings back to profit in 3rd qtr
1 December 2008
Pharming's Prodarsan completes Ph I trial
1 December 2008
MSD publishes strong migraine trial results
1 December 2008
Adolor and GSK publish Ph III Entereg results
24 November 2008
Chelsea completes enrollment in Ph Iintradialytic hypotension trial
24 November 2008
United Therapeutics plunges 33% as oral PAH drug misses Ph III endpoint, filing delay likely
24 November 2008
Actavis "confident" in Totowa's GPM standards
24 November 2008
Actelion/Roche's S1P1 to enter Ph II
24 November 2008
US FDA Review Vouchers criticized
17 November 2008
Sun extends tender offer for Taro
17 November 2008
FDA clears Celgene's first placenta-derived stem cell clinical study
17 November 2008
TorreyPines sells AD genetics program to Eisai
17 November 2008
Santhera reports strong animal data on two cachexia drugs
17 November 2008
Japan's NHI list gets 99 generics added
17 November 2008
Bayer presents results of Xarelto trial at AHA
17 November 2008
UK's RPS publishes azithromycin guidance
17 November 2008
Progenics to advance HCV entry blocker into the clinic
10 November 2008
S-P's boceprevir doubles SVR24 in Ph II study
10 November 2008
Repligen initiates Ph IIB depression trial
10 November 2008
Generex says Oral-Lyn fits ADA/EASD guidance
10 November 2008
Barr's LoSeasonique approved in the USA
3 November 2008
TorreyPines inititates dosing in Ph I pain trial
27 October 2008
Anadis gets go ahead for Ph IV BioGard trial
27 October 2008
Vertex' CF drug boosts FEV1 in G551D patients
27 October 2008
3-month FDA delay for Takeda's GERD drug
27 October 2008
Ono licenses Progenics' OIC drug in Japan
27 October 2008
UNSIC warns of gaps in flu readiness
20 October 2008
RXi licenses oral RNAi tech from US university
20 October 2008
Astex to disclose key findings on Hsp90 drug
20 October 2008
Evotec initiates Ph I study of P2X7 blocker
20 October 2008
Cyclacel fully enrolled for Ph II AML trial
20 October 2008
Japan stock market week to Oct 13, 2008
20 October 2008
Contraceptive pill part deregulation in France
20 October 2008
Exjade cuts thalassemia iron build up in organs
20 October 2008
Rotateq wins WHO pre-qualification status
20 October 2008
Daiichi Sankyo plans to become a leader in antithrombotics with prasugrel and DU-176b
20 October 2008
Study supports tablet form of Panacos' bevirimat
13 October 2008
Bayer's riociguat to enters Ph III testing
13 October 2008
Ardea's RDEA119 reduces damage in UC model
13 October 2008
Japan stock market week to Oct 6, 2008
13 October 2008
Poniard exercises $10M drawn-down option
13 October 2008
FDA rejects OTC cough and cold drug ban call
13 October 2008
Wyeth/ALS deal for antibiotic in Asia/Pac
6 October 2008
Orient gets Summit PD drooling drug rights
6 October 2008
Takeda files alogliptinand Actos NDA in USA
29 September 2008
Merck & Co in-licenses novel osteoanabolic drug from Japan Tabacco
29 September 2008
Drugs for acute severe UC to be assessed by UK's NIHR HTA
29 September 2008
Cladribine enters trial in patients at risk of MS
29 September 2008
Cyclacel's sapacitabine enters Ph II trial in MDS
22 September 2008
Repligen
22 September 2008
77% of patients on RAD001 achieve stable pancreatic NET tumors
22 September 2008
Over 200 patients enrolled in Generex' Oral-Lyn trial
22 September 2008
UK release for Basilea's Toctino
22 September 2008
New data published on DOR's orBec
22 September 2008
Cognis starts making vitamin E TPGS aimed at pharmaceutical sector
22 September 2008
EPO revokes Genentech/Biogen patent
22 September 2008
Novartis' RAD001 gets US priority review
15 September 2008
Biocon reports on oral insulin trial
15 September 2008
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
